Grand Rapids-based Tetra Therapeutics finalizes deal to sell to Japanese partner
This is an article about portfolio company, Tetra Therapeutics
Grand Rapids biopharmaceutical company Tetra Therapeutics Inc. announced this week that it has a definitive agreement to sell to a Japanese firm in a deal that could reach $500 million, according to a statement.
Tetra Therapeutics, which develops drugs for people suffering from Fragile X syndrome, Alzheimer’s disease, traumatic brain injury, and other brain disorders, has finalized a 2018 agreement with the Japanese company.
View source version on crainsdetroit.com: https://www.crainsdetroit.com/mergers-acquisitions/grand-rapids-based-tetra-therapeutics-finalizes-deal-sell-japanese-partner